In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...
Read More
In a nutshell This study examined the benefit of radiation to limited sites of cancer spread (metastases) in men no longer responding to hormone therapy. Researchers reported effective local cancer control after radiation of lymph node metastases in patients no longer responding to hormone therapy. Some background Hormone therapy is the...
Read More
In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...
Read More
In a nutshell This study examined evidence for the benefits of adding chemotherapy early to hormone therapy for metastatic prostate cancer. Authors concluded that early evidence indicates a survival benefit with the addition of chemotherapy for metastatic prostate cancer. Some background Androgen deprivation therapy (ADT) is a type of hormone...
Read More
In a nutshell This study examined the effects of enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the lungs and/or liver. Researchers reported that enzalutamide is safe and effective for men with mCRPC affecting the lung or liver. Some background When prostate cancer spreads outside of...
Read More
In a nutshell This study examined the benefit of adding chemotherapy to androgen deprivation therapy (ADT) early to treat metastatic hormone-sensitive prostate cancer. Researchers reported a survival benefit when chemotherapy was added to ADT. This benefit was only detected with chemotherapy involving docetaxel (Taxotere). Some background ADT is a...
Read More
Hormonal therapy—also known as androgen deprivation therapy—has long been used to treat prostate cancer. But how does it work? And what are the potential side effects? Prostate cancer experts Drs. Jeri Kim and Sumit K. Subudhi, from MD Anderson Cancer Center, explore approved hormonal therapy...
Read More
In a nutshell This study examined the effect of ethnicity on health outcomes with androgen deprivation therapy (ADT). Researchers reported shorter survival among African American men receiving ADT for low- or intermediate-risk prostate cancer compared to men of other ethnicities. Some background ADT is a type of hormone therapy used to treat...
Read More
In a nutshell This study examined the relationship between androgen deprivation therapy (ADT) and the risk of falls. Authors present preliminary evidence suggesting that patients receiving ADT may be at increased risk of falls. Some background ADT is a type of hormone therapy commonly used to treat advanced prostate cancer. By reducing the levels...
Read More
In a nutshell This phase 2 trial aims to compare the benefit of two types of exercise for men with metastatic castration-resistant prostate cancer. The main outcome to be investigated is the safety of the exercises and its effect on cancer pain. The trial is recruiting in San Francisco (California). The details Metastatic castration-resistant...
Read More
In a nutshell This study examined the safety and effectiveness of radium-223, alone or in combination with other therapies, in treating metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that radium-223 was well tolerated and can be safely combined with additional therapies. Combined therapies were associated with improved...
Read MoreIn a nutshell This study examined treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) progressing after treatment with abiraterone acetate (Zytiga). Chemotherapy with docetaxel (Taxotere) was the most common subsequent therapy. Authors concluded that patients with mCRPC who progress after AA may still benefit from subsequent...
Read More
